Survodutide (BI 456906)
GLP-1/glucagon dual agonist. SYNCHRONIZE-1 Phase 3 (obesity, 76 weeks): 16.6% body weight reduction vs 3.2% placebo. Dual mechanism adds GCGR-driven energy expenditure on top of GLP-1 satiety.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Boehringer Ingelheim development, Eli Lilly licensed. GLP-1R + GCGR dual agonist — the glucagon component drives hepatic fat mobilization and thermogenesis (increased energy expenditure), augmenting the GLP-1 satiety signal. SYNCHRONIZE Phase 3 program: SYNCHRONIZE-1 (obesity without T2D, 76 weeks, topline April 2026): 16.6% weight reduction, 85.1% achieved ≥5% reduction. SYNCHRONIZE-2 (obesity + T2D) still reading out. SYNCHRONIZE-CVOT (cardiovascular outcomes) — no data yet. Compared to retatrutide, lacks the GIP component; compared to semaglutide, adds the glucagon component for the NASH/MASH narrative.
Dual-sponsor bias: Boehringer Ingelheim (development) + Eli Lilly (license) both have financial interest — treat all survodutide efficacy claims as B-grade, sponsor-funded. CV safety data is pending (SYNCHRONIZE-CVOT not reporting). GI side effects class-wide. The 16.6% weight-loss signal is solid but meaningfully below retatrutide's 28.7% — context matters when users compare.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Not FDA-approved. Phase 3 ongoing (SYNCHRONIZE program). No NDA filed as of 2026-05-07. No 503A compounding path.
Pre-filled with this compound's published dose range: up to 4.8 mg once weekly (Phase 3 dose range — no approved dose) · once weekly subcutaneous — investigational only
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Lower community awareness than retatrutide or orforglipron — the dual sponsor + Boehringer-less-known positioning makes it harder to track. NASH/MASH narrative is the differentiator if glucagon-driven liver fat data emerges. Most users still waiting for CV outcome data before forming strong opinions.